Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Inclusion Criteria: * Age ≥18 and ≤75 years old * Histologically confirmed colorectal adenocarcinoma * Radiological and/or pathological confirmation of liver metastases, with ≤5 lesions * Genetic testing and/or immunohistochemistry confirmation of RAS, BRAF wild-type, and pMMR/MSS * Absence of extrahepatic metastases confirmed by CT, MRI, or PET/CT (if necessary) * Primary colorectal tumor has been or can be radically resected * Liver metastatic lesions are resectable (including radiofrequency ablation and SBRT), and postoperative NED (no evidence of disease) is expected. Resectable liver metastases are specifically defined as ① ≤5 metastatic lesions; ② R0 resection can be performed (including radiofrequency ablation and SBRT); ③ Sufficient residual liver volume is expected after resection; ④ At least one hepatic vein can be preserved after resection, with preserved blood flow in and out of the residual liver and preserved bile ducts, and can preserve at least two adjacent liver segments; ⑤ No extrahepatic metastases. * No prior anti-tumor therapy for liver metastases, except for surgical resection of primary lesions * Normal hematological function (platelets \>90×109/L; white blood cells \>3×109/L; neutrophils \>1.5×109/L) * Serum bilirubin ≤1.5 times the upper limit of normal (ULN), transaminases ≤5 times ULN, alkaline phosphatase ≤2.5 ULN, no ascites, normal coagulation function, albumin ≥35g/L * Liver function classified as Child-Pugh grade A * Serum creatinine below the…